Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02168842 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Isradipine in Early Parkinson Disease
A Phase 3 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 3
- Development phase
- 336
- Enrollment target
NCT02168842 is a Phase 3 study that has completed, run by University of Rochester. The registered enrollment target is 336 participants.
The verdict
NCT02168842, a Phase 3 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 336 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.
Interventions
- DRUG Isradipine
- DRUG Placebo (for Isradipine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02168842
The ClinicalTrials.gov registry entry for NCT02168842 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Isradipine is the first listed.
NCT02168842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02168842 about?
NCT02168842 is a clinical study titled "Efficacy of Isradipine in Early Parkinson Disease". The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.
What is the current status of trial NCT02168842?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 336 participants. The study started on 2014-11. Estimated completion is 2018-11.
What interventions are being tested in trial NCT02168842?
The interventions under investigation include: Isradipine (DRUG), Placebo (for Isradipine) (DRUG).
Who is sponsoring clinical trial NCT02168842?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.